
浏览全部资源
扫码关注微信
华中科技大学同济医学院 附属普爱医院(武汉市第四医院),武汉 430033
吴刚,硕士,主治医师,从事心血管内科疾病诊疗与科研究工作,E-mail:www2016aa@163.com
胡立群,主任医师,硕士生导师,从事心血管疾病的临床、科研、教授工作,E-mail:hyy885a@163.com
收稿日期:2020-05-22,
网络出版日期:2020-07-27,
纸质出版日期:2021-01-05
移动端阅览
吴刚,余德龙,李磊等.麝香通心滴丸对缺血性心力衰竭心肌纤维化和血管再生的影响机制[J].中国实验方剂学杂志,2021,27(01):141-146.
WU Gang,YU De-long,LI Lei,et al.Influence Mechanism of Myocardial Fibrosis and Vascular Regeneration of Shexiang Tongxin Pills to Syndrome of Qi Deficiency and Blood Stasis in Ischemic Heart Failure[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(01):141-146.
吴刚,余德龙,李磊等.麝香通心滴丸对缺血性心力衰竭心肌纤维化和血管再生的影响机制[J].中国实验方剂学杂志,2021,27(01):141-146. DOI: 10.13422/j.cnki.syfjx.20201034.
WU Gang,YU De-long,LI Lei,et al.Influence Mechanism of Myocardial Fibrosis and Vascular Regeneration of Shexiang Tongxin Pills to Syndrome of Qi Deficiency and Blood Stasis in Ischemic Heart Failure[J].Chinese Journal of Experimental Traditional Medical Formulae,2021,27(01):141-146. DOI: 10.13422/j.cnki.syfjx.20201034.
目的
2
评价麝香通心滴丸治疗缺血性心力衰竭(IHF)气虚血瘀证的临床疗效及对心肌纤维化和血管再生的影响机制。
方法
2
将140例患者按1∶1随机数字表法分为对照组和观察组各70例,对照组脱落、失访3例,剔除1例,完成66例;观察组脱落、失访4例,剔除1例,完成65例。两组患者参照指南给予综合治疗措施。对照组口服麝香通心滴丸模拟药,2丸/次,3次/d。观察组口服麝香通心滴丸,2丸/次,3次/d。均连续治疗24周。进行治疗前后超声心动图检查,测量左心室射血分数(LVEF),心输出量(CO),左室舒张末期内径(LVEDd),左室后壁厚度(LVPW),左室质量指数(LVMI)和左室重构指数(LVRI);进行治疗前后6 min步行试验(6 MWT),Lee氏心衰评分、气虚血瘀证评分和明尼苏达心力衰竭生活质量调查表(MLHFQ)评分;检测治疗前后N末端B型利钠肽原(NT-proBNP),转化生长因子-
β
1
(TGF-
β
1
),可溶性ST2(sST2),基质金属蛋白酶-2(MMP-2),基质金属蛋白酶抑制因子-2(TIMP-2),胰岛素样生长因子-1(IGF-1),血管内皮生长因子(VEGF),血管生成素1(Ang1)和血管生成素2(Ang2)。进行安全性评价。
结果
2
观察组临床疗效总有效率为90.77%(59/65),高于对照组的74.24%(49/66)(
<math id="M1"><msup><mrow><mi>χ</mi></mrow><mrow><mn mathvariant="normal">2</mn></mrow></msup></math>
http://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=22539907&type=
http://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=22539906&type=
2.96333337
3.13266659
=6.179,
P
<
0.05);观察组LVEF,CO和LVRI均高于对照组(
P
<
0.05),LVEDd,LVPW,LVMI均低于对照组(
P
<
0.05);观察组6 MWT多于对照组(
P
<
0.01),Lee氏心衰、气虚血瘀证和MLHFQ评分均低于对照组(
P
<
0.01);观察组NT-proBNP,TGF-
β
1
,sST2,MMP-2水平均低于对照组(
P
<
0.01),TIMP-2水平高于对照组(
P
<
0.01);观察组IGF-1,VEGF,Ang1水平均高于对照组(
P
<
0.01),Ang2水平低于对照组(
P
<
0.01)。没有发现服用麝香通心滴丸相关不良反应。
结论
2
在西医常规治疗的基础上,给予麝香通心滴丸治疗IHF气虚血瘀证患者,可通过影响心肌纤维化和血管再生因子,改善心室重构,提高患者心脏功能,减轻临床症状,增加患者的运动耐量和生活质量,有着较好的临床疗效与安全性。
Objective
2
To discuss clinical effect of Shexiang Tongxin pills to syndrome of Qi deficiency and blood stasis in ischemic heart failure (IHF) and to study the mechanism to myocardial fibrosis and vascular regeneration.
Method
2
One hundred and forty patients were randomly divided into observation group (70 cases) and control group (70 cases) with the same cases. 66 patients in control group finish the therapy (3 patients fall off or lost visit, 1 were eliminated). 65 patients in observation group completed the therapy (4 patients were falling off, 1 were eliminated). Both groups patients got combined treatment according to the guiding. Patients in control group got simulated medicine of Shexiang Tongxin pills, 2 pills/time, 3 times/day. Patients in observation group got Shexiang Tongxin pills, 2 pills/time, 3 times/day. The treatment was continued for 24 weeks. Before and after treatment, the left ventricular ejection fraction (LVEF), cardiac output (CO), end diastolic diameter (LVEDd), left posterior wall thickness (LVPW), left ventricular mass index (LVMI) and left ventricular remodeling index (LVRI) were measured by echocardiography. And scores of six minute walking test (6 MWT), Lee's heart failure score, Qi deficiency and blood stasis syndrome score and Minnesota Heart Failure Quality of life questionnaire (MLHFQ) were graded. And levels of N-terminal B-type natriuretic peptide (NT-proBNP), transforming growth factor-
β
1
(TGF-
β
1
), soluble ST2 (sST2), matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase inhibitor-2 (TIMP-2), insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF), angiopoietin1 (Ang1) and angiopoietin2 (Ang2), and the safety was evaluated.
Result
2
The total clinical effect in observation group was 90.77% (59/65) higher than 74.24% (49/66) in control group (
<math id="M2"><msup><mrow><mi>χ</mi></mrow><mrow><mn mathvariant="normal">2</mn></mrow></msup></math>
http://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=22539909&type=
http://html.publish.founderss.cn/rc-pub/api/common/picture?pictureId=22539908&type=
3.30199981
3.64066648
=6.179,
P
<
0.05). Levels of LVEF, CO, LVRI, 6 MWT, TIMP-2, IGF-1, VEGF and Ang1 were higher than those in control group (
P
<
0.01). And levels of LVEDd, LVPW and LVMI were lower than those in control group (
P
<
0.05), levels of NT-proBNP, TGF-
β
1
, sST2, MMP-2 and Ang2 were lower than those in control group (
P
<
0.01), scores of Lee's heart failure score, Qi deficiency and blood stasis syndrome score and MLHFQ were lower than those in control group (
P
<
0.01). Besides, there was no adverse reactions caused by Shexiang Tongxin dropping pills.
Conclusion
2
On the basis of conventional western medicine treatment, Shexiang Tongxin drop pills can improve the ventricular remodeling, improve the heart function, reduce the clinical symptoms, increase the exercise tolerance and quality of life of the patients by affecting the myocardial fibrosis and vascular regeneration factor, which has better clinical efficacy and safety.
陈榆舒 , 陈伟 , 郑捷 , 等 . 心脏磁共振成像评价缺血性心力衰竭心肌纤维化研究进展及应用 [J]. 中国医学影像技术 , 2016 , 32 ( 3 ): 449 - 452 .
LAL H , AHMAD F , ZHOU J , et al . Cardiac fibroblast glycogen synthase kinase-3 β regulates ventricular remodeling and dysfunction in ischemic heart [J]. Circulation , 2014 , 130 ( 5 ): 419 - 430 .
CHEN K , YAN M , LI Y , et al . Intermedin153 enhances angiogenesis and attenuates adverse remodeling following myocardial infarction by activating AMP activated protein kinase [J]. Mol Med Rep , 2017 , 15 ( 4 ): 1497 - 1506 .
王洁 , 蒋捷 , 褚松筠 , 等 . 慢性缺血性心力衰竭患者指南指导下的用药现状 [J]. 中国临床药理学杂志 , 2019 , 35 ( 24 ): 3183 - 3186 .
中国中西医结合学会心血管疾病专业委员会 . 慢性心力衰竭中西医结合诊疗专家共识 [J]. 中国中西医结合杂志 , 2016 , 36 ( 2 ): 133 - 141 .
陈照云 , 黄兴 , 周立华 , 等 . 麝香通心滴丸药物作用机制和药物靶点的研究进展 [J]. 河南中医 , 2019 , 39 ( 7 ): 1117 - 1121 .
韩松洁 , 张晓雨 , 张立晶 , 等 . 麝香通心滴丸对PCI术后患者慢血流的临床证据评价 [J]. 世界科学技术—中医药现代化 , 2018 , 20 ( 10 ): 1772 - 1777 .
吴刚 , 胡立群 . 麝香通心滴丸联合盐酸曲美他嗪对缺血性心力衰竭患者神经激素-细胞因子及左心室重构的影响 [J]. 辽宁中医杂志 , 2019 , 46 ( 4 ): 677 - 680 .
中华医学会心血管病学分会心力衰竭学组 . 中国心力衰竭诊断和治疗指南2018 [J]. 中华心血管病杂志 , 2018 , 46 ( 10 ): 760 - 789 .
王华 , 李莹莹 , 柴坷 , 等 . 中国住院心力衰竭患者流行病学及治疗现状 [J]. 中华心血管病杂志 , 2019 , 47 ( 11 ): 865 - 874 .
赵希曦 , 杨洁红 , 曹雪滨 , 等 . 论心血瘀阻是冠心病慢性心力衰竭的基本病机与证型 [J]. 中华中医药杂志 , 2020 , 35 ( 2 ): 827 - 830 .
罗良涛 , 赵慧辉 , 王娟 , 等 . 中医医院冠心病慢性心力衰竭患者中医证候要素分布特点分析 [J]. 北京中医药大学学报 , 2014 , 37 ( 2 ): 130 - 134 .
李福智 , 侯阳 . 人参茎叶总皂苷对肾上腺素致家兔肺水肿的保护机制研究 [J]. 中国现代医学杂志 , 2019 , 29 ( 14 ): 1 - 6 .
陈瀛澜 , 郝艳艳 , 郭夫江 , 等 . 蟾酥化学成分及药理活性研究进展 [J]. 中草药 , 2017 , 48 ( 12 ): 2579 - 2588 .
代晓光 , 苏长兰 . 丹参化学成分及药理研究进展 [J]. 中医药信息 , 2018 , 35 ( 4 ): 126 - 129 .
刘源香 , 李谨 , 杨继国 . 麝香的药理作用及临床应用研究概况 [J]. 山东中医杂志 , 2014 , 33 ( 8 ): 693 - 694 .
GAO H , BO Z , WANG Q , et al . Salvanic acid B inhibits myocardial fibrosis through regulating TGF- β 1 /Smad signaling pathway [J]. Biomed Pharmacother , 2019 , 110 : 685 - 691 .
YU C , WANG W , JIN X . Hirudin protects ang II-Induced myocardial fibroblasts fibrosis by inhibiting the extracellular signal-regulated kinase1/2 (ERK1/2) pathway [J]. Med Sci Monit , 2018 , 24 : 6264 - 6272 .
VIANELLO E , DOZIO E , TACCHINI , et al . ST2/IL-33 signaling in cardiac fibrosis [J]. Int J Biochem Cell Biol , 2019 , 116 : 105619 .
MARNEROS A G . Effects of chronically increased VEGF-A on the aging heart [J]. FASEB J , 2018 , 32 ( 3 ): 1550 - 1565 .
LI C , MATSUSHITA S , LI Z , et al . C-kit positive cardiac outgrowth cells demonstrate better ability for cardiac recovery against ischemic myopathy [J]. J Stem Cell Res Ther , 2017 , 7 ( 10 ): 402 .
NICOLINI G , FORINI F , KUSMIC C , et al . Angiopoietin 2 signal complexity in cardiovascular disease and cancer [J]. Life Sci , 2019 , 15 ( 239 ): 117080 .
0
浏览量
23
下载量
7
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621